14 results
Keyword Tazemetostat Remove keyword
-
List item
Orphan designation: Tazemetostat for: Treatment of malignant mesothelioma
Date of designation: 21/03/2018, Positive, Last updated: 13/10/2021Tazemetostat Overview On 21 March 2018 … Ireland Limited, Ireland, for tazemetostat for the treatment of malignant … from studies indicate that tazemetostat might stop the disease getting … -
List item
Orphan designation: Tazemetostat for: Treatment of follicular lymphoma
Date of designation: 21/03/2018, Positive, Last updated: 13/10/2021Tazemetostat Overview On 21 March 2018 … Ireland Limited, Ireland, for tazemetostat for the treatment of follicular … medicine expected to work? Tazemetostat blocks the action of a protein … -
List item
Orphan designation: Tazemetostat for: Treatment of diffuse large B-cell lymphoma
Date of designation: 21/03/2018, Positive, Last updated: 13/10/2021Tazemetostat Overview On 21 March 2018 … Ireland Limited, Ireland, for tazemetostat for the treatment of diffuse … medicine expected to work? Tazemetostat blocks the action of a protein … -
List item
Human medicine European public assessment report (EPAR): Kymriah
tisagenlecleucel, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 22/08/2018,
, 
, Revision: 13, Authorised, Last updated: 07/11/2022
-
List item
COMP: Agendas, minutes and meeting reports (updated)
Last updated: 17/03/2023 -
List item
Paediatric Committee (PDCO): 20-23 July 2021
Virtual meeting, from 20/07/2021 to 23/07/2021, Last updated: 21/02/2022 -
List item
Paediatric Committee (PDCO): 7-10 September 2021
Online, from 07/09/2021 to 10/09/2021, Last updated: 09/09/2021 -
List item
PDCO: Agendas, minutes and reports
Last updated: 21/02/2023 -
List item
Committee for Orphan Medicinal Products (COMP): 13-15 February 2018
European Medicines Agency, London, UK, from 13/02/2018 to 15/02/2018, Last updated: 19/02/201414 2.1.11. Tazemetostat - EMA/OD/222/17 … 16 2.1.13. Tazemetostat - EMA/OD/217/17 … -
List item
Committee for Orphan Medicinal Products (COMP): 17-19 April 2018
European Medicines Agency, London, UK, from 17/04/2018 to 19/04/2018, Last updated: 16/04/2018 -
List item
Committee for Orphan Medicinal Products (COMP): 11-13 September 2018
European Medicines Agency, London, UK, from 11/09/2018 to 13/09/2018, Last updated: 06/12/2018 -
List item
Committee for Orphan Medicinal Products (COMP): 17-19 July 2018
European Medicines Agency, London, UK, from 17/07/2018 to 19/07/2018, Last updated: 19/06/2014 -
List item
Committee for Orphan Medicinal Products (COMP): 19-21 June 2018
European Medicines Agency, London, UK, from 19/06/2018 to 21/06/2018, Last updated: 17/08/2018 -
List item
Guidance documents
Last updated: 19/07/2022